Greenwich Lifesciences Stock Today

GLSI Stock  USD 11.61  0.60  4.91%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Average

 
High
 
Low
Greenwich Lifesciences is trading at 11.61 as of the 18th of March 2025. This is a 4.91 percent decrease since the beginning of the trading day. The stock's open price was 12.21. Greenwich Lifesciences has over 55 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 18th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
25th of September 2020
Category
Healthcare
Classification
Health Care
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. The company has 13.14 M outstanding shares of which 653.14 K shares are currently shorted by private and institutional investors with about 31.07 trading days to cover. More on Greenwich Lifesciences

Moving together with Greenwich Stock

  0.7VANI Vivani Medical Earnings Call This WeekPairCorr

Moving against Greenwich Stock

  0.45VALN Valneva SE ADR Earnings Call TodayPairCorr
  0.43DVAX Dynavax TechnologiesPairCorr

Greenwich Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities251.7 K265 K
Notably Down
Slightly volatile
Total Assets14 MM
Way Up
Slightly volatile
Total Current Assets14 MM
Way Up
Slightly volatile
Debt Levels
Greenwich Lifesciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Greenwich Lifesciences' financial leverage. It provides some insight into what part of Greenwich Lifesciences' total assets is financed by creditors.
Liquidity
Greenwich Lifesciences currently holds 294.41 K in liabilities. Greenwich Lifesciences has a current ratio of 64.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Greenwich Lifesciences' use of debt, we should always consider it together with its cash and equity.

Change In Working Capital

26,933.36
Greenwich Lifesciences (GLSI) is traded on NASDAQ Exchange in USA. It is located in Building 14, Stafford, TX, United States, 77477 and employs 3 people. Greenwich Lifesciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 160.5 M. Greenwich Lifesciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 13.14 M outstanding shares of which 653.14 K shares are currently shorted by private and institutional investors with about 31.07 trading days to cover. Greenwich Lifesciences currently holds about 15.64 M in cash with (6.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22.
Check Greenwich Lifesciences Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Greenwich Lifesciences is $160.5 Million. Greenwich Lifesciences secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Greenwich Ownership Details

Greenwich Stock Institutional Holders

InstituionRecorded OnShares
Strs Ohio2024-09-30
12.8 K
Bank Of New York Mellon Corp2024-12-31
11.2 K
Barclays Plc2024-12-31
9.6 K
Bank Of America Corp2024-12-31
7.3 K
Jpmorgan Chase & Co2024-12-31
7.1 K
Ubs Group Ag2024-12-31
6.6 K
Rhumbline Advisers2024-12-31
6.5 K
New York State Common Retirement Fund2024-12-31
K
Citigroup Inc2024-12-31
4.9 K
Blackrock Inc2024-12-31
357.8 K
Vanguard Group Inc2024-12-31
275 K
View Greenwich Lifesciences Diagnostics

Greenwich Lifesciences Historical Income Statement

As of now, Greenwich Lifesciences' Total Operating Expenses is increasing as compared to previous years. The Greenwich Lifesciences' current Total Other Income Expense Net is estimated to increase to about 526.5 K, while Depreciation And Amortization is projected to decrease to 3,971. View More Fundamentals

Greenwich Stock Against Markets

Greenwich Lifesciences Corporate Management

When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.81)
Return On Assets
(0.90)
Return On Equity
(1.52)
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.